Abstract Funding Acknowledgements Type of funding sources: None. Background Glucagone Like Peptide-1 Receptor Agonists (GLP-1RAs) are incretine-based glucose-lowering drugs widely used in the treatment Diabetes Mellitus type 2 (DM2). Several cardiovascular outcomes trials demonstrated that GLP-1RAs capable to induce a reduction major adverse events (MACE) DM2 patients with atherosclerotic disea...

Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a subanalysis SWITCH-SEMA 1 study, multicenter, prospective, randomized, parallel-group trial compar...